Peter JM Openshaw

Prof. Peter JM Openshaw

orcid

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2020 in Nature
Verified
Journal Article
Closed access
PDF file
EPErola Pairo-Castineira
Erola Pairo-Castineira
SCSara Clohisey
Sara Clohisey
LKLucija Klaric
Lucija Klaric
ABAndrew D. Bretherick
Andrew D. Bretherick
KRKonrad Rawlik
Konrad Rawlik
JBJ. Kenneth Baillie
J. Kenneth Baillie

4 September 2020 in Nature Immunology
Verified
Journal Article
Open access
PDF file
YPYanchun Peng
Yanchun Peng
AMAlexander Mentzer
Alexander Mentzer
GLGuihai Liu
Guihai Liu
XYXuan Yao
Xuan Yao
ZYZixi Yin
Zixi Yin
JKJulian Knight
Julian Knight
The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and therapeutics will depend on understanding viral immunity. We studied T cell memory in 42 patients following recovery from COVID-19 (28 with mild disease and 14 with severe disease) and 16 unexposed donors, using interferon-γ-based assays with peptides spanning SARS-CoV-2 except ORF1. The breadth and magnitude of T cell responses were significantly higher in severe as compared with mild cases. Total and spike-specific T cell responses correlated with spike-specific antibody responses. We identified 41 peptides containing CD4+ and/or CD8+ epitopes, including six immunodominant regions. Six optimized CD8+ epitopes were defined, with peptide–MHC pentamer-positive cells displaying the central and effector memory phenotype. In mild cases, higher proportions of SARS-CoV-2-specific CD8+ T cells were observed. The identification of T cell responses associated with milder disease will support an understanding of protective immunity and highlights the potential of including non-spike proteins within future COVID-19 vaccine design.

1 July 2006 in The Lancet
Verified
Journal Article
Closed access
RSRosalind L Smyth
Rosalind L Smyth
POPeter JM Openshaw
Peter JM Openshaw

1 March 2021 in Cell
Verified
Journal Article
Open access
ETEmma Thomson
Emma Thomson
LRLaura E. Rosen
Laura E. Rosen
JSJames G. Shepherd
James G. Shepherd
RSRoberto Spreafico
Roberto Spreafico
AFAna da Silva Filipe
Ana da Silva Filipe
GSGyorgy Snell
Gyorgy Snell
SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Herein we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S, and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild-type. We show the N439K mutation confers resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the FDA, and reduces the activity of some polyclonal sera from persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics.

31 March 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BKBen Killingley
Ben Killingley
AMAlex J. Mann
Alex J. Mann
MKMariya Kalinova
Mariya Kalinova
ABAlison Boyers
Alison Boyers
NGNiluka Goonawardane
Niluka Goonawardane
CCChristopher Chiu
Christopher Chiu

1 October 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
NMNatalie I Mazur
Natalie I Mazur
DHDeborah Higgins
Deborah Higgins
MNMarta Nunes
Marta Nunes
JMJosé A Melero
José A Melero
ALAnnefleur C Langedijk
Annefleur C Langedijk
LBLouis J Bont
Louis J Bont
The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.